Nabriva Therapeutics PLC – (NASDAQ:NBRV) Director Buys $20,659.31 in Stock

Nabriva Therapeutics PLC – (NASDAQ:NBRV) Director Colin Md Broom purchased 10,177 shares of Nabriva Therapeutics stock in a transaction dated Friday, August 30th. The shares were purchased at an average price of $2.03 per share, with a total value of $20,659.31. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Colin Md Broom also recently made the following trade(s):

  • On Wednesday, August 21st, Colin Md Broom sold 10,177 shares of Nabriva Therapeutics stock. The shares were sold at an average price of $2.07, for a total transaction of $21,066.39.

NBRV traded up $0.04 during midday trading on Friday, reaching $2.06. The company’s stock had a trading volume of 1,366,978 shares, compared to its average volume of 2,790,362. The company has a debt-to-equity ratio of 0.56, a current ratio of 5.67 and a quick ratio of 5.67. Nabriva Therapeutics PLC – has a 1 year low of $1.12 and a 1 year high of $3.27. The stock’s 50-day moving average is $2.21 and its 200-day moving average is $2.38.

Nabriva Therapeutics (NASDAQ:NBRV) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.04. The business had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.88 million. Nabriva Therapeutics had a negative net margin of 3,602.24% and a negative return on equity of 139.52%. Analysts anticipate that Nabriva Therapeutics PLC – will post -1.1 earnings per share for the current fiscal year.

NBRV has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 23rd. ValuEngine raised shares of Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub downgraded shares of Nabriva Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th. Bank of America set a $6.00 price target on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 20th. Finally, HC Wainwright set a $7.00 price target on shares of Nabriva Therapeutics and gave the stock a “buy” rating in a research note on Sunday, August 18th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company’s stock. Nabriva Therapeutics currently has an average rating of “Buy” and a consensus target price of $7.17.

A number of institutional investors and hedge funds have recently made changes to their positions in NBRV. FMR LLC grew its holdings in Nabriva Therapeutics by 77.0% in the first quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock worth $7,958,000 after purchasing an additional 1,418,800 shares during the period. Fosun International Ltd purchased a new stake in Nabriva Therapeutics in the first quarter worth about $1,593,000. Renaissance Technologies LLC grew its holdings in Nabriva Therapeutics by 51.8% in the second quarter. Renaissance Technologies LLC now owns 1,299,365 shares of the biotechnology company’s stock worth $3,157,000 after purchasing an additional 443,600 shares during the period. JPMorgan Chase & Co. grew its holdings in Nabriva Therapeutics by 92.7% in the second quarter. JPMorgan Chase & Co. now owns 323,857 shares of the biotechnology company’s stock worth $719,000 after purchasing an additional 155,815 shares during the period. Finally, Morgan Stanley grew its holdings in Nabriva Therapeutics by 52.9% in the second quarter. Morgan Stanley now owns 265,418 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 91,869 shares during the period. Institutional investors and hedge funds own 3.10% of the company’s stock.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Recommended Story: Why does the United States have a lingering trade deficit?

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.